In the phase 3 clinical trial (NCT02993523) of venetoclax plus azacytidine, 66.7% of NPM1-mutated AML patients achieved CR + CRi [65], a majority of them being negative for measurable residual disease (MRD). Here, NPM1 is linked to acute myeloid leukemia.